The dopaminergic basis of human behaviors: A review of molecular imaging studies

Abstract

This systematic review describes human molecular imaging studies which have investigated alterations in extracellular DA levels during performance of behavioral tasks. Whilst heterogeneity in experimental methods limits meta-analysis, we describe the advantages and limitations of different methodological approaches. Interpretation of experimental results may be limited by regional cerebral blood flow (rCBF) changes, head movement and choice of control conditions. We revisit our original study of striatal DA release during video-game playing (Koepp et al., 1998) to illustrate the potentially confounding influences of head movement and alterations in rCBF. Changes in [ 11 C]raclopride binding may be detected in extrastriatal as well as striatal brain regions -however we review evidence which suggests that extrastriatal changes may not be clearly interpreted in terms of DA release. Whilst several investigations have detected increases in striatal extracellular DA concentrations during task components such as motor learning and execution, reward-related processes, stress and cognitive performance, the presence of potentially biasing factors should be carefully considered (and, where possible, accounted for) when designing and interpreting future studies.

Multimodal MR Imaging of Brain Iron in Attention Deficit Hyperactivity Disorder: A Noninvasive Biomarker That Responds to Psychostimulant Treatment?

“…Changes in brain iron and/or dopaminergic functional units are associated with alterations in motivation, attention, working memory, and motor control (11)(12)(13)35). This behavioral overlap may be due to iron's involvement in maintaining dopamine homeostasis and may explain why high concentrations of both brain iron and dopamine are co-localized to the same basal ganglia regions (11,29).…”

Measuring Endogenous 5-HT Release by Emission Tomography: Promises and Pitfalls

“…This approach has been widely applied to the study of the dopaminergic system in which neuroreceptor mapping using the radiotracers [ 11 C]raclopride or [ 123 I]IBZM have been combined with pharmacological challenges that elicit dopamine release (Laruelle, 2000). Even nonpharmacological, physiologic changes in endogenous dopamine may be measurable (Egerton et al, 2009). These challenge studies have contributed to a vast new understanding of brain dopaminergic mechanisms in schizophrenia (Abi-Dargham, 2004), Parkinson's disease (Brooks, 2006), and stimulant abuse (Narendran and Martinez, 2008).…”

Optimized In Vivo Detection of Dopamine Release Using 18F-Fallypride PET

“…Until now, most PET experiments on dopamine D 2/3 neurotransmission have used the specific dopamine benzamide antagonist 11 C-raclopride (4). Because of its low affinity and hence limited capacity to measure extrastriatal D 2/3 receptors, the role of extrastriatal dopamine release in the mechanism of responses to reinforcing stimuli has received much less attention.…”